Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: Administration for complex coronary intervention
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Both the magnitude and the duration of pharmacodynamic response to xemilofiban were enhanced by prior abciximab treatment. The potentiated pharmacodynamic response was not evident after 1 week. This observation has implications for the safety and efficacy of sequential parenteral-oral GP IIb/IIIa blockade therapy and may be useful in deriving dose regimens for orally administered compounds.